A largely invisible layer of gene regulation — not the DNA sequence itself but chemical tags on RNA — may hold the key to understanding why immune systems turn against the body. For millions living with conditions like lupus, rheumatoid arthritis, or multiple sclerosis, this molecular frontier represents a genuinely new class of drug targets distinct from conventional immunosuppressants.

N6-methyladenosine (m6A) is the most abundant internal modification on messenger RNA in mammals, and the enzymes that install this mark — collectively called "writers," principally the METTL3/METTL14/WTAP complex — govern how quickly transcripts are translated, degraded, or exported from the nucleus. This review in Acta Pharmacologica Sinica systematically maps the structural domains of each writer protein, catalogs how dysregulated m6A deposition skews T-cell differentiation, macrophage polarization, and dendritic cell activation, and surveys emerging small-molecule inhibitors targeting the METTL3 catalytic pocket as potential immunomodulatory agents.

Placing this within the broader epitranscriptomics landscape, m6A research has accelerated dramatically since high-resolution mapping tools became available around 2012, yet the autoimmune angle remains comparatively underexplored relative to its oncology applications. The mechanistic logic is compelling: because writer complexes act upstream of many inflammatory gene networks simultaneously, a single targeted inhibitor could dampen pathological immune activation without globally suppressing immune defense — a longstanding problem with steroids and broad immunosuppressants. However, critical limitations deserve emphasis. Most mechanistic evidence to date derives from mouse models or cell-line studies; human clinical validation is sparse. Writer enzymes are also expressed in virtually every tissue, raising real concerns about off-target toxicity with systemic inhibition. This review is best understood as an expert synthesis of preclinical groundwork rather than near-term clinical guidance — incremental but strategically important for researchers mapping the next generation of precision immunotherapy targets.